Compare Johnson & Johnson (JNJ) vs Unilever plc (UL) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Unilever (UL) trades at $62.18, down 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings missed expectations, but the company maintains strong profitability with a 46.95% gross margin and 18.75% net margin. Key developments include a pending food business divestiture to McCormick and a $270 million innovation center investment, signaling strategic focus on core brands and digital transformation.

The outlook is mixed: valuation appears fair with a P/E of 21.15, but earnings misses and competitive pressures pose risks. Analyst consensus is cautious with 51% hold ratings. Long-term opportunities lie in emerging market growth and cost efficiencies, though near-term execution and macroeconomic headwinds require monitoring.